US 11359246
Treatment of obesity with G-protein coupled receptor 75 (GPR75) inhibitors
granted A61KA61K31/7105A61K38/465
Quick answer
US patent 11359246 (Treatment of obesity with G-protein coupled receptor 75 (GPR75) inhibitors) held by REGENERON PHARMACEUTICALS, INC. expires Mon Jun 09 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- REGENERON PHARMACEUTICALS, INC.
- Grant date
- Tue Jun 14 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Jun 09 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 29
- CPC classes
- A61K, A61K31/7105, A61K38/465, A61P, A61P3/04